100 Participants Needed

Xenon-129 for Interstitial Lung Disease

(Xe MRI in ILD Trial)

AB
JW
Overseen ByJason Woods, PhD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Children's Hospital Medical Center, Cincinnati
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to develop a new method using a special type of MRI to monitor changes in interstitial lung diseases (ILDs) over time. The focus is on using a gas called 129Xe to predict disease progression and treatment response. Participants will either have ILD or be healthy controls. The study seeks individuals with a clinical diagnosis of ILD from a certified lung doctor.

As an unphased trial, this study offers participants a unique opportunity to contribute to groundbreaking research that could enhance future ILD diagnostics and treatments.

Do I have to stop taking my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that this protocol is safe for detecting disease activity in interstitial lung diseases?

Studies have shown that Xenon-129 is generally safe for lung imaging. Clinical trials tested it on 83 adults with lung problems, and the results indicated that Xenon-129 was well-tolerated without causing serious side effects. This gas enhances MRI scans, providing a clearer view of lung function. It is important to note that Xenon-129 is not a treatment for lung disease but a tool to help doctors better understand lung function. This understanding can aid in developing new treatments for lung conditions.12345

Why are researchers excited about this trial?

Researchers are excited about this trial because it uses MRI and biological assays to evaluate explanted lungs, specifically looking at participants with Interstitial Lung Disease (ILD). Unlike traditional methods that might rely solely on symptomatic assessment or invasive biopsies, this approach provides a non-invasive and detailed way to study lung tissue and function. By combining advanced imaging with biological analysis, the trial aims to uncover new insights into lung health and disease progression, potentially leading to better diagnostic tools and treatment strategies for ILD in the future.

What evidence suggests that this protocol is effective for detecting disease activity in interstitial lung diseases?

Studies have shown that a special type of MRI using hyperpolarized Xenon-129 (129Xe) can help detect issues with lung gas exchange, particularly in lung diseases like interstitial lung diseases (ILDs). Research indicates that individuals with lung fibrosis exhibit different 129Xe readings compared to healthy individuals. For instance, one study found that the amount of air moving through the lungs is usually lower in people with ILD. This trial will include participants with diagnosed ILD and healthy controls to further investigate these findings. These findings suggest that 129Xe MRI could be a useful tool for monitoring lung health and assessing the effectiveness of treatments for lung conditions. Early results also show promise in using 129Xe as a marker to predict disease progression and patient response to treatment.26789

Who Is on the Research Team?

JW

Jason Woods, PhD

Principal Investigator

Children's Hospital Medical Center, Cincinnati

Are You a Good Fit for This Trial?

Inclusion Criteria

You are agreeable to provide informed permission and comply with visit/protocol timelines (Permission must be obtained prior to any research activities being executed.)
You are an adult (age >18) of either gender and not hospitalized.
You have been clinically diagnosed with Interstitial Lung Disease by a certified pulmonologist, according to established standards

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Initial MRI and biological assays to establish baseline metrics for participants

1 day
1 visit (in-person)

Data Collection and Analysis

Participants undergo 129Xe MRI to collect data on lung function and gas exchange metrics

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after data collection

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Xenon-129

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: ILDExperimental Treatment1 Intervention
Group II: ControlExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Children's Hospital Medical Center, Cincinnati

Lead Sponsor

Trials
844
Recruited
6,566,000+

Citations

Hyperpolarized Xenon-129: A New Tool to Assess Pulmonary ...

The quantification of dissolved 129Xe can provide data on gas-exchange derangements in lung disease. In animal studies, lung fibrosis results in ...

Hyperpolarized 129Xe MR Spectroscopy in the Lung ...

In a prospective study, reduced lung function at hyperpolarized 129Xe MRI and extent of fibrotic structure at CT were associated with ...

Hyperpolarized Xenon-129 MRI: Narrative Review of ...

Publications using 129XeMRI to assess clinical observations or outcomes in pulmonary diseases such as chronic obstructive pulmonary disease (COPD), asthma, ...

Imaging biomarkers of lung ventilation in interstitial ...

Regarding 129Xe biomarkers, the ventilation volume fraction was lower in all ILD groups than in HV (Xe-VVF: HV mean ± std. 97.4 ± 2.6, CTD-ILD: 91.0 ± 4.8, p = ...

Hyperpolarized 129-Xenon MRI in Fibrosing Interstitial ...

This project aims to investigate the potential of non-invasive imaging to identify and monitor the earliest signs and physiological effects of pulmonary ...

XENOVIEW (xenon Xe 129 hyperpolarized), for oral inhalation

The safety of XENOVIEW was evaluated in two prospective efficacy trials that enrolled a total of 83 adult patients with various lung disorders who were being ...

MEARIS™ | Publication | ntap | NTP221017PBF9L - CMS

HP Xe 129 is a new chemical entity performing as a signaling agent when used in chest MRI to evaluate lung function throughout the lung, including the pulmonary ...

Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary ...

The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to ...

Lung Abnormalities Detected with Hyperpolarized 129 Xe ...

Hyperpolarized xenon 129 MRI and total lung diffusion capacity for carbon monoxide demonstrate significantly impaired gas transfer in nonhospitalized ...